GC patients with positive HER3 expression had apparently decreased 1-year (OR = 1.85, 95%CI 1.32–2.58, P < 0.001, Fig. 7a), 3-year (OR = 1.53, 95%CI 1.27–1.85, P < 0.001, Fig. 7b) and 5-year (OR = 2.18, 95%CI 1.15–4.14, P = 0.02, Fig. 7c) survival rates compared with patients negative for HER3. The gene discussed is ERBB3; the disease is gastric cancer.